Disaster Relief Contributions, New Medical Trials, Clinical Results and Employee Incentives - Research Report on UnitedHealth Group, ACADIA, USANA, Portola and Horizon Pharma

NEW YORK, November 21, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting UnitedHealth Group, Inc. (NYSE: UNH), ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD), USANA Health Sciences Inc. (NYSE: USNA), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) and Horizon Pharma, Inc. (NASDAQ: HZNP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

UnitedHealth Group, Inc. Research Report

On November 15, 2013, UnitedHealth Group, Inc. (UnitedHealth) announced that United Health Foundation is partnering with Project HOPE, a US-based charity, to help Filipinos affected by typhoon Haiyan receive urgent medical care and critical medical supplies. According to UnitedHealth, the Foundation and employees of the Company have committed at least $750,000 to fund Project HOPE's efforts. The Company said that Project HOPE, working in conjunction with the US Navy, will deliver medical supplies, and assemble and deploy teams of volunteer nurses and physicians to disaster recovery sites in the Philippines to deliver critical medical care to people affected by the typhoon. United Health Foundation donations will directly fund the cost of delivering these teams to the Philippines. The Full Research Report on UnitedHealth Group, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/73e5_UNH

--

ACADIA Pharmaceuticals, Inc. Research Report

On November 14, 2013, ACADIA Pharmaceuticals, Inc. (ACADIA) announced that it has initiated a Phase II feasibility trial designed to examine the efficacy and safety of pimavanserin as a treatment for patients with Alzheimer's disease psychosis (ADP).  ACADIA stated that no drug is approved in the United States to treat ADP and the off-label use of current antipsychotics is linked to increased mortality, serious adverse events, and cognitive decline in elderly patients with dementia-related psychosis. Executive Vice President of Development and Chief Medical Officer Roger G. Mills, M.D. said, "We are delighted to pursue this clinical study in collaboration with Professor Ballard and King's College London. We believe that their unique clinical research infrastructure and expertise will provide access to a pool of well-characterized ADP patients and enable the use of a small and geographically-focused group of highly trained raters, which we expect to enhance study precision." The Full Research Report on ACADIA Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/3eb7_ACAD

--

USANA Health Sciences Inc. Research Report

On November 12, 2013, USANA Health Sciences Inc. (USANA) announced that the USANA True Health Foundation donated $20,000 to International Relief Teams (IRT), a nonprofit international humanitarian organization, to aid victims of Super Typhoon Haiyan. According to the Company, this is the third donation sent to support relief efforts in the Philippines from the charitable foundation established by USANA Health Sciences Inc., since its inception in 2012. USANA stated that the money donated by the Foundation for emergency aid will serve 15,000 people for one week, which includes immediate survival essentials such as clean water, water purification tablets and food. The Full Research Report on USANA Health Sciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ee40_USNA

--

Portola Pharmaceuticals, Inc. Research Report

On November 11, 2013, Portola Pharmaceuticals, Inc. (Portola) announced initial results from a Phase 2 proof-of-concept study of andexanet alfa, its investigational Factor Xa inhibitor antidote, in healthy volunteers who were administered the Factor Xa inhibitor XARELTO (rivaroxaban). According to the Company, results from the first two dosing cohorts of the study demonstrated that andexanet alfa is able to dose-dependently reverse the anticoagulant effects of XARELTO. Portola informed that these data, as well as data from additional cohorts evaluating higher doses of andexanet alfa, will be presented in a poster session on December 9, 2013 at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in New Orleans from December 7, 2013 to December 10, 2013. The Full Research Report on Portola Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/102f_PTLA

--

Horizon Pharma, Inc. Research Report

On November 12, 2013, Horizon Pharma, Inc. (Horizon Pharma) announced that on November 7, 2013 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 156,550 shares of common stock to 26 new employees. The Company stated that each stock option has an exercise price per share equal to $3.74, the fair market value on the grant date, and vests over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. Horizon Pharma also mentioned that each stock option has a ten year term and is subject to the terms and conditions of the Company's 2011 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted. The Full Research Report on Horizon Pharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/05ea_HZNP

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner